CCAP

Crescent Capital BDC Inc

Add to Watchlist

Advanced Chart

15.280

+0.14(0.925%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

15.500

Open

15.170

VWAP

15.32

Vol

157.07K

Mkt Cap

566.30M

Low

15.170

Amount

2.41M

EV/EBITDA(TTM)

13.47

Total Shares

37.06M

1.44B

EV/OCF(TTM)

22.92

P/S(TTM)

3.75

Crescent Capital BDC, Inc. is a specialty finance company focused on lending to middle-market companies. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It invests primarily in secured debt, including first lien, unitranche first lien and second-lien debt, and unsecured debt, including mezzanine and subordinated debt, as well as related equity securities of private United States middle-market companies. It is focused on purchasing interests in loans or making debt investments, either directly from its target companies as primary market or private credit investments (private credit transactions), or primary or secondary market bank loans or high-yield transactions in the syndicated market (syndicated loans and bonds). Although its focus is on investing in less liquid private credit transactions. The Company is managed by Crescent Cap Advisors, LLC.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q1

FY2024Q4

42.52M

-13.14%

0.467

-20.9%

45.08M

-10.48%

0.525

-16.67%

47.27M

-5.39%

0.560

-8.2%

Estimates Revision

The market is revising No Change the revenue expectations for Crescent Capital BDC, Inc. (CCAP) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -0.71%.

Revenue Estimates for FY2024

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2024

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-0.71%

In Past 3 Month

5 Analyst Rating

12.57% Upside

Wall Street analysts forecast CCAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCAP is 17.20 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

12.57% Upside

Current: 15.280

Low

15.00

Averages

17.20

High

20.00

12.57% Upside

Current: 15.280

Low

15.00

Averages

17.20

High

20.00

Keefe Bruyette

Market Perform -> Outperform

upgrade

$17

2025-07-23

Reason

Keefe Bruyette

Price Target

$17

2025-07-23

upgrade

Market Perform -> Outperform

Reason

Keefe Bruyette upgraded Crescent Capital BDC to Outperform from Market Perform with a $17 price target. Keefe expects a stable quarter for business development company earnings results, with fewer headwinds from rates and spreads, and activity slowed, but exited the quarter at a good pace and could set up a stronger second half, the analyst tells investors in a research note.

Keefe Bruyette

Market Perform -> Outperform

upgrade

$17

2025-07-22

Reason

Keefe Bruyette

Price Target

$17

2025-07-22

upgrade

Market Perform -> Outperform

Reason

Keefe Bruyette upgraded Crescent Capital BDC to Outperform from Market Perform with an unchanged price target of $17.

BofA

Buy

downgrade

$20 -> $17

2025-06-01

Reason

BofA

Price Target

$20 -> $17

2025-06-01

downgrade

Buy

Reason

BofA lowered the firm's price target on Crescent Capital BDC to $17 from $20 and keeps a Buy rating on the shares. The Q1 results for the business development companies were "somewhat disappointing," with profitability weaker than expected as lower rates and spreads, tariff-related macro uncertainty, and normalizing credit weighted on reports, the analyst tells investors in a research note. However, there was only as small uptick in non-accruals to 2.9%, which remain well below the industry longer-term average, adds BofA. It remains positive on the sector.

Keefe Bruyette

Outperform -> Market Perform

downgrade

$17

2025-05-16

Reason

Keefe Bruyette

Price Target

$17

2025-05-16

downgrade

Outperform -> Market Perform

Reason

Keefe Bruyette downgraded Crescent Capital BDC to Market Perform from Outperform with a price target of $17, down from $18.50. The company's earnings missed this quarter and it will be difficult for the shares to trade significantly higher if its credit quality is not holding up, the analyst tells investors in a research note. The firm cites some recent credit issues and an operating return on equity that is now at the lower end of the sector for the downgrade.

Wells Fargo

Finian O'Shea

Equal Weight

downgrade

$16 -> $15

2025-05-16

Reason

Wells Fargo

Finian O'Shea

Price Target

$16 -> $15

2025-05-16

downgrade

Equal Weight

Reason

Wells Fargo analyst Finian O'Shea lowered the firm's price target on Crescent Capital BDC to $15 from $16 and keeps an Equal Weight rating on the shares. The firm says that Falling base rates are likely a strong headwind to Crescent Capital BDC given its tighter net interest margin profile.

Raymond James

Outperform

NULL

downgrade

$20 -> $17

2025-05-16

Reason

Raymond James

Price Target

$20 -> $17

2025-05-16

downgrade

Outperform

NULL

Reason

Raymond James lowered the firm's price target on Crescent Capital BDC to $17 from $20 and keeps an Outperform rating on the shares. While fourth quarter results were well below the firm's estimates, Raymond James continues to see an attractive risk/reward, with a conservatively implemented variable dividend policy, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Crescent Capital BDC Inc (CCAP.O) is 6.82, compared to its 5-year average forward P/E of 8.49. For a more detailed relative valuation and DCF analysis to assess Crescent Capital BDC Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

8.49

Current PE

6.82

Overvalued PE

10.12

Undervalued PE

6.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.95

Current PS

3.03

Overvalued PS

4.91

Undervalued PS

2.99